NASH
Low-Dose Aspirin Reduces Liver Fat in Patients With MASLD in Phase 2 Trial
A daily dose of aspirin led to a significant reduction in liver fat in patients with metabolic ...
AUGUST 2, 2024
FDA Approves Resmetirom, First Drug for MASH
The FDA granted accelerated approval to the first medication for the treatment of MASH, Rezdiffra.
MARCH 16, 2024
Despite Some Setbacks, Strong Specialty Pipeline Seen in 2024
2023 was a record year for new drug approvals, and while 2024 will probably not exceed that record, specialty ...
FEBRUARY 15, 2024
Pegozafermin Shows Promise for Treating MASH
The new drug pegozafermin could offer a promising treatment for patients with metabolic ...
DECEMBER 15, 2023
NASH: An Interesting Space to Watch
Dr. Aimee Tharaldson, a keynote speaker at AMCP Nexus 2023, spoke with us about the pipeline for nonalcoholic ...
OCTOBER 20, 2023
NASH Dash: The Pipeline Race is on for New Agents
The year 2022 could see, for the first time, FDA-approved medications for nonalcoholic steatohepatitis (NASH). ...
JANUARY 7, 2022
Trial Results Mixed for Frontrunning NASH Therapy
For treatment of non-alcoholic steatohepatitis, obeticholic acid met one of its primary end points but not the ...
MARCH 18, 2020
Rare Diseases and Oncology Top List of 2015 Specialty Drug Approvals
Rare diseases and oncology topped the list of new drug approvals in 2015, according to a new Diplomat report.
JANUARY 19, 2016
